• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纤维板层型肝细胞癌的肝切除与肝移植治疗结果

Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma.

作者信息

El-Gazzaz G, Wong W, El-Hadary M K, Gunson B K, Mirza D F, Mayer A D, Buckels J A, McMaster P

机构信息

Liver Unit, Queen Elizabeth Hospital, Birmingham, UK.

出版信息

Transpl Int. 2000;13 Suppl 1:S406-9. doi: 10.1007/s001470050372.

DOI:10.1007/s001470050372
PMID:11112043
Abstract

Fibrolamellar hepatocellular carcinoma (FL HCC) is an uncommon variant of hepatocellular carcinoma occurring usually in non-cirrhotic livers. Hepatic resection or transplantation offers the only chance of cure. We reviewed our experience of surgery for FL HCC from 1985-1998. Twenty patients with FL HCC (13 females and 7 males) median age 27 years (range 12-69) were treated either by hepatic resection [n = 11; extended right hepatectomy (5), extended left hepatectomy (1), right hemihepatectomy (2), left hemihepatectomy (2), left lateral segmentectomy (1)] or, if the disease was non-resectable, by transplantation (n = 9). The median follow up was 25 months (1-63). The prognostic factors analysed included size [less than 5 cm (3 patients), more than 5 cm (17 patients)], number [solitary (16 patients), multiple (4 patients)], capsular invasion (6 patients), vascular invasion (11 patients) and lymph node invasion (6 patients). The overall survival at 1, 3 and 5 years was 89.5, 75 and 50%, respectively. The liver resection survival was better than liver transplantation survival at 3 years 100 vs 76%, respectively (P < 0.025). Although all prognostic factors analysed did not show a significant difference, there is tendency that tumour stage was the most significant for prognosis. Most of the patients in this study are young and presented without specific symptoms, with normal liver function range and had no tumour marker to help in diagnosis. As a result most of our patients were diagnosed late. However the outcome of surgical intervention was favourable.

摘要

纤维板层型肝细胞癌(FL HCC)是肝细胞癌的一种罕见变异类型,通常发生于非肝硬化肝脏。肝切除或肝移植是唯一的治愈机会。我们回顾了1985年至1998年期间FL HCC的手术治疗经验。20例FL HCC患者(13例女性,7例男性),中位年龄27岁(范围12 - 69岁),接受了肝切除治疗(n = 11;扩大右肝切除术(5例)、扩大左肝切除术(1例)、右半肝切除术(2例)、左半肝切除术(2例)、左外侧段切除术(1例)),如果疾病不可切除,则接受肝移植治疗(n = 9)。中位随访时间为25个月(1 - 63个月)。分析的预后因素包括肿瘤大小[小于5 cm(3例患者)、大于5 cm(17例患者)]、数量[单发(16例患者)、多发(4例患者)]、包膜侵犯(6例患者)、血管侵犯(11例患者)和淋巴结侵犯(6例患者)。1年、3年和5年的总生存率分别为89.5%、75%和50%。肝切除术后3年生存率优于肝移植术后生存率,分别为100%和76%(P < 0.025)。虽然分析的所有预后因素均未显示出显著差异,但肿瘤分期对预后的影响有增大趋势。本研究中的大多数患者较为年轻,就诊时无特异性症状,肝功能正常范围,且无肿瘤标志物辅助诊断。因此,我们的大多数患者诊断较晚。然而,手术干预的结果是良好的。

相似文献

1
Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma.纤维板层型肝细胞癌的肝切除与肝移植治疗结果
Transpl Int. 2000;13 Suppl 1:S406-9. doi: 10.1007/s001470050372.
2
Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients.肝细胞癌的外科治疗:198例肝切除与肝移植经验
World J Surg. 1991 Mar-Apr;15(2):270-85. doi: 10.1007/BF01659064.
3
Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation.采用肝次全切除术或肝移植治疗纤维板层样肝癌。
Hepatology. 1997 Oct;26(4):877-83. doi: 10.1002/hep.510260412.
4
Outcome of patients with fibrolamellar hepatocellular carcinoma.纤维板层型肝细胞癌患者的预后
Cancer. 2006 Mar 15;106(6):1331-8. doi: 10.1002/cncr.21703.
5
Fibrolamellar hepatocellular carcinoma at a tertiary centre in South Africa: a case series.南非一家三级医疗中心的纤维板层型肝细胞癌:病例系列
S Afr J Surg. 2009 Nov;47(4):108-11.
6
Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience.纤维板层肝细胞癌的临床特征和手术治疗效果:单中心回顾性分析。
World J Surg Oncol. 2020 May 12;18(1):93. doi: 10.1186/s12957-020-01855-2.
7
Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria.米兰标准范围内行部分肝切除术治疗肝细胞癌的结果。
Br J Surg. 2011 Sep;98(9):1292-300. doi: 10.1002/bjs.7583. Epub 2011 Jun 7.
8
Living donor liver transplantation or resection for Child-Pugh A hepatocellular carcinoma patients with multiple nodules meeting the Milan criteria.对于符合米兰标准的多发性结节Child-Pugh A级肝细胞癌患者,进行活体供肝肝移植或肝切除术。
Transpl Int. 2014 Jun;27(6):562-9. doi: 10.1111/tri.12297. Epub 2014 Apr 2.
9
[Surgical therapy of hepatic fibrolamellar carcinoma].肝纤维板层癌的外科治疗
Ann Ital Chir. 2007 Jan-Feb;78(1):53-8.
10
Anatomical versus non-anatomical resection for solitary hepatocellular carcinoma without macroscopic vascular invasion: A propensity score matching analysis.无肉眼可见血管侵犯的孤立性肝细胞癌的解剖性切除与非解剖性切除:一项倾向评分匹配分析
J Gastroenterol Hepatol. 2017 Apr;32(4):870-878. doi: 10.1111/jgh.13603.

引用本文的文献

1
Liver cancer multiomics reveals diverse protein kinase A disruptions convergently produce fibrolamellar hepatocellular carcinoma.肝癌多组学研究揭示多种蛋白激酶A破坏作用会共同导致纤维板层型肝细胞癌。
Nat Commun. 2024 Dec 30;15(1):10887. doi: 10.1038/s41467-024-55238-2.
2
Liver transplantation vs liver resection in HCC: promoting extensive collaborative research through a survival meta-analysis of meta-analyses.肝细胞癌肝移植与肝切除术的比较:通过荟萃分析的生存荟萃分析促进广泛的合作研究。
Front Oncol. 2024 Mar 18;14:1366607. doi: 10.3389/fonc.2024.1366607. eCollection 2024.
3
A Multidisciplinary Approach to the Management of Fibrolamellar Carcinoma: Current Perspectives and Future Prospects.
纤维板层癌管理的多学科方法:当前观点与未来展望
Onco Targets Ther. 2022 Oct 3;15:1095-1103. doi: 10.2147/OTT.S296127. eCollection 2022.
4
Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event.纤维板层型肝细胞癌:一种罕见但不良的病症。
World J Gastrointest Oncol. 2022 Jun 15;14(6):1103-1114. doi: 10.4251/wjgo.v14.i6.1103.
5
Development and validation of a nomogram for predicting the cancer-specific survival of fibrolamellar hepatocellular carcinoma patients.建立并验证用于预测纤维板层型肝细胞癌患者肿瘤特异性生存的列线图模型。
Updates Surg. 2022 Oct;74(5):1589-1599. doi: 10.1007/s13304-022-01308-3. Epub 2022 Jun 17.
6
Trans-arterial therapy for Fibrolamellar carcinoma: A case report and literature review.经动脉治疗纤维板层状癌:一例报告及文献综述。
Int J Surg Case Rep. 2022 May;94:106980. doi: 10.1016/j.ijscr.2022.106980. Epub 2022 Mar 29.
7
Liver Transplantation for Pediatric Hepatocellular Carcinoma: A Systematic Review.小儿肝细胞癌的肝移植:一项系统评价
Cancers (Basel). 2022 Mar 2;14(5):1294. doi: 10.3390/cancers14051294.
8
Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma.与单纯肝细胞癌相比,罕见肝细胞癌变异体的临床结局
J Hepatocell Carcinoma. 2019 Jul 22;6:119-129. doi: 10.2147/JHC.S215235. eCollection 2019.
9
Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma.纤维板层型肝细胞癌的临床病理特征及预后
J Gastrointest Oncol. 2019 Jun;10(3):554-561. doi: 10.21037/jgo.2019.01.35.
10
Fibrolamellar variant of hepatocellular carcinoma presenting during pregnancy: management dilemmas.妊娠期间出现的纤维板层型肝细胞癌:治疗困境
Ann Hepatobiliary Pancreat Surg. 2017 Feb;21(1):48-51. doi: 10.14701/ahbps.2017.21.1.48. Epub 2017 Feb 28.